Analysts see higher drug sales for Cephalon
Meanwhile, cancer drug Treanda will likely continue gaining favor and use as an initial treatment for lung cancer and non-Hodgkin’s lymphoma, said Leerink Swann & Co. analyst Gary Nachman, also citing a survey of physicians.
This entry was posted on Friday, June 20th, 2008 at 12:41 pm and is filed under Research, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.